[go: up one dir, main page]

WO2002083727A3 - Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse - Google Patents

Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse Download PDF

Info

Publication number
WO2002083727A3
WO2002083727A3 PCT/EP2002/004090 EP0204090W WO02083727A3 WO 2002083727 A3 WO2002083727 A3 WO 2002083727A3 EP 0204090 W EP0204090 W EP 0204090W WO 02083727 A3 WO02083727 A3 WO 02083727A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
hyperplasies
tumors
thyroid
acid sequences
Prior art date
Application number
PCT/EP2002/004090
Other languages
English (en)
French (fr)
Other versions
WO2002083727A2 (de
Inventor
Joern Bullerdiek
Original Assignee
Joern Bullerdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joern Bullerdiek filed Critical Joern Bullerdiek
Priority to AU2002310840A priority Critical patent/AU2002310840A1/en
Priority to JP2002581482A priority patent/JP2005503123A/ja
Priority to EP02735249A priority patent/EP1377607A2/de
Publication of WO2002083727A2 publication Critical patent/WO2002083727A2/de
Publication of WO2002083727A3 publication Critical patent/WO2002083727A3/de
Priority to US10/684,042 priority patent/US20050095594A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Die vorliegende Erfindung betrifft eine Nukleinsäure mit bei Hyperplasien und/oder Tumoren geänderter Expression, wobei die Nukleinsäure eine Nukleinsäuresequenz umfasst, die ausgewählt ist aus Gruppe, die SEQ.ID.No. 1 bis 12 und SEQ.ID.No. 16-19 umfasst.
PCT/EP2002/004090 2001-04-12 2002-04-12 Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse WO2002083727A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002310840A AU2002310840A1 (en) 2001-04-12 2002-04-12 Nucleic acid sequences of hyperplasies and tumors of the thyroid
JP2002581482A JP2005503123A (ja) 2001-04-12 2002-04-12 甲状腺の過形成と腫瘍の核酸配列
EP02735249A EP1377607A2 (de) 2001-04-12 2002-04-12 Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
US10/684,042 US20050095594A1 (en) 2001-04-12 2003-10-10 Nucleic acid sequences of hyperplasies and tumors of the thyroid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10118452.2 2001-04-12
DE10118452A DE10118452A1 (de) 2001-04-12 2001-04-12 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/684,042 Continuation US20050095594A1 (en) 2001-04-12 2003-10-10 Nucleic acid sequences of hyperplasies and tumors of the thyroid

Publications (2)

Publication Number Publication Date
WO2002083727A2 WO2002083727A2 (de) 2002-10-24
WO2002083727A3 true WO2002083727A3 (de) 2003-04-17

Family

ID=7681480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004090 WO2002083727A2 (de) 2001-04-12 2002-04-12 Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse

Country Status (5)

Country Link
EP (1) EP1377607A2 (de)
JP (1) JP2005503123A (de)
AU (1) AU2002310840A1 (de)
DE (1) DE10118452A1 (de)
WO (1) WO2002083727A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005011003B9 (de) * 2004-03-03 2009-02-26 Universität Leipzig Verfahren und Mittel zur differentiellen Diagnose von Schilddrüsentumoren
WO2006117217A2 (de) * 2005-05-04 2006-11-09 Noxxon Pharma Ag Neue verwendung von spiegelmeren
US8828656B2 (en) 2009-08-31 2014-09-09 University Of Bremen Microrna-based methods and compositions for the diagnosis, prognosis and treatment of tumor involving chromosomal rearrangements
US10404099B1 (en) 2018-02-28 2019-09-03 Corning Optical Communications LLC Intermediate power supply unit for distributing lower voltage power to remote power distribution systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033982A2 (en) * 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033982A2 (en) * 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANTONINI P ET AL: "CYTOGENETIC ABNORMALITIES IN THYROID ADENOMAS", CANCER GENETICS AND CYTOGENETICS, vol. 52, no. 2, 1991, pages 157 - 164, XP002204612, ISSN: 0165-4608 *
BELGE G ET AL: "Delineation of a 150-kb breakpoint cluster in benign thyroid tumors with 19q13.4 aberrations.", CYTOGENETICS AND CELL GENETICS, vol. 93, no. 1-2, 2001, pages 48 - 51, XP002204613, ISSN: 0301-0171 *
BELGE G ET AL: "FISH analyses of a newly established thyroid tumor cell line showing a t(1;19)(p35 or p36:1;q13) reveal that the breakpoint lies between 19q13.3-13.4 and 19q13.4.", CYTOGENETICS AND CELL GENETICS, vol. 69, no. 3-4, 1995, pages 220 - 222, XP002204605, ISSN: 0301-0171 *
BELGE G. ET AL.: "Zytogenetische Veränderungen bei benignen Schilddrüsenhyperplasien und Adenomen korrelieren mit der Histologie", VERH. DTSCH. GES. PATH., vol. 81, 1997, pages 151 - 156, XP002204607 *
BELGE GAZANFER ET AL: "Breakpoints of 19q13 translocations of benign thyroid tumors map within a 400 kilobase region.", GENES CHROMOSOMES & CANCER, vol. 20, no. 2, 1997, pages 201 - 203, XP002204604, ISSN: 1045-2257 *
BELGE GAZANFER ET AL: "Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology.", CANCER GENETICS AND CYTOGENETICS, vol. 101, no. 1, February 1998 (1998-02-01), pages 42 - 48, XP002204606, ISSN: 0165-4608 *
BICHER ANNETTE ET AL: "Loss of heterozygosity in human ovarian cancer on chromosome 19q.", GYNECOLOGIC ONCOLOGY, vol. 66, no. 1, 1997, pages 36 - 40, XP002204610, ISSN: 0090-8258 *
CLOSS ELLEN I ET AL: "Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: Three related carriers with distinct transport properties.", BIOCHEMISTRY, vol. 36, no. 21, 1997, pages 6462 - 6468, XP002204608, ISSN: 0006-2960 *
GEORGE M YOUSEF ET AL: "Prostase/KLK-L1 is a new member of the human Kallikrein gene family, is espressed in prostate and breast tissues, and is hormonally regulated", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 17, 1 September 1999 (1999-09-01), pages 4252 - 4256, XP002141958, ISSN: 0008-5472 *
GUPTA RAJNISH K ET AL: "The t(14:18) chromosomal translocation and Bcl-2 protein expression in Hodgkin's disease.", LEUKEMIA (BASINGSTOKE), vol. 8, no. 8, 1994, pages 1337 - 1341, XP002204611, ISSN: 0887-6924 *
HOSOKAWA HIROSHI ET AL: "Cloning and characterization of a brain-specific cationic amino acid transporter", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 13, 1997, pages 8717 - 8722, XP002193512, ISSN: 0021-9258 *
WANSCHURA SYLKE ET AL: "Mapping of the translocation breakpoints of primary pleomorphic adenomas and lipomas within a common region of chromosome 12.", CANCER GENETICS AND CYTOGENETICS, vol. 86, no. 1, 1996, pages 39 - 45, XP002204609, ISSN: 0165-4608 *

Also Published As

Publication number Publication date
JP2005503123A (ja) 2005-02-03
DE10118452A1 (de) 2002-10-31
WO2002083727A2 (de) 2002-10-24
EP1377607A2 (de) 2004-01-07
AU2002310840A1 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
WO1999057325A3 (en) Enzymes mixture
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2002059260A3 (en) Nucleic acids and polypeptides
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
JP2001515920A5 (de)
WO2002028891A3 (fr) Listeria innocua, genome et applications
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
EP1209228A3 (de) Promotoren, die auf Umweltstress reagieren
WO2003035878A3 (de) Lipase-varianten
WO2003035667A3 (en) Telomerase interference
WO2002044340A3 (en) Novel nucleic acids and polypeptides
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
EP1167523A3 (de) Insertionselemente von ralstonia solanacearum
AU2001295456A1 (en) Nucleotide sequences which code for the gora gene
WO2001048185A3 (en) Transcription regulatory sequences derived from chlamydomonas reinhardtii
ZA200100332B (en) Novel nucleotide sequences coding for the ptsH gene.
AU2001278509A1 (en) Nucleotide sequences which code for the atr43 gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002735249

Country of ref document: EP

Ref document number: 10684042

Country of ref document: US

Ref document number: 2002581482

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002735249

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642